Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer

Daniel W. Visscher, Vernon Shane Pankratz, Marta Santisteban, Carol Reynolds, Ari Ristimäki, Robert A. Vierkant, Wilma L Lingle, Marlene H. Frost, Lynn C. Hartmann

Research output: Contribution to journalArticle

47 Scopus citations


Background: The cyclooxygenase-2 (COX-2) enzyme, which is induced by inflammatory and mitogenic stimuli, plays a protumorigenic role in several human cancers. COX-2 is overexpressed in invasive and in situ breast cancers. Atypical hyperplasia in breast tissue, although benign, is associated with a high risk of breast cancer. We investigated whether COX-2 overexpression in atypical hyperplasia is associated with the risk of subsequent breast cancer. Methods: COX-2 expression was assessed immunohistochemically in archival sections from 235 women with atypia whose biopsy specimens were obtained at the Mayo Clinic from January 1, 1967, through December 31, 1991. COX-2 expression was scored as 0 (negative), 1+ (weak), 2+ (moderate), or 3+ (strong). Risk factor information and follow-up for breast cancer events were obtained via a study questionnaire and the medical records. All statistical tests were two-sided. Results: Forty-one (17%) of the 235 women developed breast cancer during a median follow-up of 15 years. Moderate (category 2+) or strong (category 3+) COX-2 expression was identified in 71 (30%) and 34 (14%) of the 235 samples, respectively. The risk for developing breast cancer, relative to a control population (the Iowa Surveillance, Epidemiology, and End Results registry), increased with increasing COX-2 expression (relative risk [RR] = 2.63, 95% confidence interval [CI] = 1.56 to 4.15, for those with negative or weak COX-2 expression; RR = 3.56, 95% CI = 1.94 to 5.97, for those with moderate expression; and RR = 5.66, 95% CI = 2.59 to 10.75, for those with strong expression; P =. 07). Overexpression of COX-2 was statistically significantly associated with the type of atypia (lobular vs ductal, P <. 001), number of foci of atypia in the biopsy (P =. 02), and older age at time of biopsy (>45 years, P =. 01). Conclusions: COX-2 appears to be a biomarker that further stratifies breast cancer risk among women with atypia and may be a relevant target for chemoprevention strategies.

Original languageEnglish (US)
Pages (from-to)421-427
Number of pages7
JournalJournal of the National Cancer Institute
Issue number6
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Visscher, D. W., Pankratz, V. S., Santisteban, M., Reynolds, C., Ristimäki, A., Vierkant, R. A., Lingle, W. L., Frost, M. H., & Hartmann, L. C. (2008). Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. Journal of the National Cancer Institute, 100(6), 421-427.